Nxera Pharma announces that its subsidiary, Nxera Pharma Japan, has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for… read more.
Pacira BioSciences, Inc. announced a strategic partnership with Molteni Farmaceutici to expand access to opioid-sparing postsurgical pain management across European markets. Through this partnership, Molteni Farmaceutici will receive… read more.
AstraZeneca has entered into an agreement to invest $2 billion in newly issued equity in Summit Therapeutics Inc. to accelerate the development of ivonescimab, a first-in-class bispecific antibody… read more.
Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America upon regulatory approval…. read more.
Sanofi and Cheplapharm, a European leader in well-established medicines, announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of… read more.
BioMarin Pharmaceutical Inc. announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International… read more.
Abbott announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott’s Lingo biowearable with Google’s expertise… read more.
Nurix Therapeutics, Inc. announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the… read more.
Pfizer Japan Inc. and Eisai Co., Ltd. announced that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec OD Tablet 75mg… read more.
Organon announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA, a hormone-free, copper intrauterine device (IUD). Please see our prior… read more.
Shionogi & Co., Ltd. announced that they have completed the transfer of all rights for Radicava (edaravone), including intellectual property rights and sales rights, in major countries and… read more.
Pelthos Therapeutics Inc. announced it has acquired Xeglyze (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
